Gland Pharma Q3 PAT up 33.77% at Rs273cr on EBITDA margin expansion of 300 bps at 36%

23 Jan 2022 , 07:32 PM

Gland Pharma Ltd reported 23.73% growth yoy in total revenues for the Dec-21 quarter on consolidated basis at Rs1,063.33cr. On a sequential basis, the revenues were lower for the quarter by -1.59%.

During the quarter, the company saw 10% revenue growth in the core market comprising of US, Canada, EU and Australia at Rs665cr. The India revenues were 31% higher yoy at Rs195cr while revenues from the rest of the world were up 88% at Rs203cr.

Total R&D expenses stood at 6.6% of revenues. In Q3, Gland filed 18 ANDAs and 3 DMFs and got 4 ANDA approvals.

The consolidated Profit after tax (PAT) for the Dec-21 quarter was up 33.77% at Rs273.03cr on the back of the EBITDA margins rising 300 bps to 36% in the quarter. However, on a sequential basis, the net profits were down -9.62%.

EBITDA was up 32% yoy at Rs395cr in the third quarter. Net margins expanded from 23.75% in the Dec-20 quarter to 25.68% in the Dec-21 quarter. Net margins were lower sequentially by 228 basis points.

Financial highlights for Dec-21 compared yoy and sequentially

	Gland Pharma
Rs in Crore	Dec-21	Dec-20	YOY	Sep-21	QOQ
Total Income (Rs cr)	₹ 1,063.33	₹ 859.42	23.73%	₹ 1,080.47	-1.59%
Net Profit (Rs cr)	₹ 273.03	₹ 204.11	33.77%	₹ 302.08	-9.62%
Diluted EPS (Rs)	₹ 16.62	₹ 12.82		₹ 18.37
Net Margins	25.68%	23.75%		27.96%